What is Theravance Biopharma's R&D?

Theravance Biopharma (TBPH) reported R&D of $5.83M in Q1 2026.

How has Theravance Biopharma's R&D changed year-over-year?

Theravance Biopharma's R&D decreased by 49.1% year-over-year, from $11.45M to $5.83M.

What is the long-term trend for Theravance Biopharma's R&D?

Over 4 years (2021 to 2025), Theravance Biopharma's R&D has grown at a -33.7% compound annual growth rate (CAGR), from $193.66M to $37.41M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Theravance Biopharma TBPH R&D

R&D at other companies

Zevra Therapeutics, Inc.ZVRA

$4.39M+34.8%

LQD

Liquidia CorporationLQDA

$12.57M+80.5%

Royalty PharmaRPRX

$39.79M-21.2%

United TherapeuticsUTHR

$138.2M-7.2%

Aurinia PharmaceuticalsAUPH

$7.47M+30.1%

PrecigenPGEN

$5.64M-46.2%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's R&D?: Theravance Biopharma (TBPH) reported R&D of $5.83M in Q1 2026.
How has Theravance Biopharma's R&D changed year-over-year?: Theravance Biopharma's R&D decreased by 49.1% year-over-year, from $11.45M to $5.83M.
What is the long-term trend for Theravance Biopharma's R&D?: Over 4 years (2021 to 2025), Theravance Biopharma's R&D has grown at a -33.7% compound annual growth rate (CAGR), from $193.66M to $37.41M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.